Enzymatica AB (SE:ENZY)

:ENZY

ENZY

Enzymatica AB

RESEARCH TOOLSreports

Enzymatica AB (ENZY) Price & Analysis

0 Followers

ENZY Stock Chart & Stats

kr2.00

-kr0.34(-10.43%)

At close: Mar 06 4:00 PM EST

kr2.00

-kr0.34(-10.43%)

Day’s Range― - ―

52-Week Rangekr1.60 - kr4.15

Previous CloseN/A

Volume634.97K

Average Volume (3M)93.66K

Market Cap

kr747.62M

Enterprise Valuekr715.51M

Total Cash (Recent Filing)kr33.13M

Total Debt (Recent Filing)kr1.02M

Price to Earnings (P/E)―

Beta0.27

Next Earnings

Apr 23, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.05

Shares Outstanding242,735,100

10 Day Avg. Volume44,136

30 Day Avg. Volume93,658

Financial Highlights & Ratios

PEG Ratio0.36

Price to Book (P/B)3.71

Price to Sales (P/S)8.56

P/FCF Ratio-11.19

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.3

Revenue Forecast (FY)kr109.00M

Bulls Say, Bears Say

Bulls Say

Low Leverage / Balance Sheet StrengthVery low and declining debt materially reduces financial risk and gives management optionality to fund operations, pursue partnerships or weather seasonal demand. Over a 2–6 month horizon this under‑levered position supports continuity despite operating losses, lowering refinancing pressure.

Recovering Revenue TrendA clear uptick in annual revenue in 2025 after prior volatility suggests improving product traction and market penetration. If sustained, this trend improves operating leverage prospects and provides a base to scale marketing and distribution investment over the medium term.

Partner + Direct Distribution Business ModelA hybrid model—direct sales where they operate and partner-led distribution elsewhere—lowers capital intensity and enables faster geographic reach. Durable partner channels can drive steady wholesale volumes and reduce fixed selling costs, supporting scalability over months.

Bears Say

Persistent Negative Cash FlowContinued negative operating and free cash flow indicates the business consumes cash to run and grow. Over 2–6 months this necessitates external funding or cost cuts, constraining strategic flexibility and raising dilution or liquidity risk if revenue improvement stalls.

Sustained UnprofitabilityDeep, recurring operating losses show the cost base is not yet aligned with sales. Without durable margin improvement, profitability remains out of reach, limiting retained earnings to fund growth and increasing reliance on external capital to sustain operations.

Equity Erosion And Weak ReturnsMaterial declines in equity and strongly negative returns on equity signify capital erosion from repeated losses. This weakens the balance sheet buffer over the medium term and can reduce investor appetite for follow-on financing, raising execution risk for strategic plans.

ENZY FAQ

What was Enzymatica AB’s price range in the past 12 months?

Enzymatica AB lowest stock price was kr1.60 and its highest was kr4.15 in the past 12 months.

What is Enzymatica AB’s market cap?

Enzymatica AB’s market cap is kr747.62M.

When is Enzymatica AB’s upcoming earnings report date?

Enzymatica AB’s upcoming earnings report date is Apr 23, 2026 which is in 18 days.

How were Enzymatica AB’s earnings last quarter?

Enzymatica AB released its earnings results on Feb 18, 2026. The company reported -kr0.05 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.05.

Is Enzymatica AB overvalued?

According to Wall Street analysts Enzymatica AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Enzymatica AB pay dividends?

Enzymatica AB does not currently pay dividends.

What is Enzymatica AB’s EPS estimate?

Enzymatica AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Enzymatica AB have?

Enzymatica AB has 242,735,100 shares outstanding.

What happened to Enzymatica AB’s price movement after its last earnings report?

Enzymatica AB reported an EPS of -kr0.05 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 12.462%.

Which hedge fund is a major shareholder of Enzymatica AB?

Currently, no hedge funds are holding shares in SE:ENZY

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Enzymatica AB

Enzymatica AB, a life science company, develops and sells medical devices for infection-related diseases. The company's product includes ColdZyme mouth spray, which prevents common cold and reduces the duration of illness. It also provides enzyme formulations. The company sells mouth spray under the ViruProtect brand in Denmark; STADAProtect brand in Germany; Psysiomer Stop Virus brand in France; and Zerinol Virus Defense brand in Italy. Enzymatica AB was incorporated in 2007 and is headquartered in Lund, Sweden.